Journal of psychosomatic research · 2026
Treatment effects of multimodal inpatient psychotherapy for post-COVID patients: First results from a non-randomized, controlled study.
СтатьяКонтролируемое клиническое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koller Katharina, Hanc Evelyne, Herold Regina, Kastel-Hoffmann Silke, Morawa Eva, Erim Yesim
Аннотация
BACKGROUND: Evidence-based treatment options for post-COVID syndrome remain limited. This study evaluated the effectiveness of a five-week inpatient psychosomatic treatment program for post-COVID patients.
METHODS: In this prospective non-randomized controlled trial, patients with confirmed post-COVID syndrome were recruited from a specialized Post-COVID Center and allocated, based on treatment preference, either to a five-week multimodal inpatient psychosomatic program (intervention group) or to treatment-as-usual without inpatient psychosomatic care (control group). Outcomes were assessed at baseline (T0) and after five weeks (T1). Measures included post-COVID symptom severity (PCS score), fatigue (FSS), depressive symptoms (PHQ-9), anxiety (GAD-7), health-related quality of life (SF-36), and illness-related coping competence (PCQ-2). Group differences over time were analyzed using repeated-measures analysis of covariance, controlling for the T0-T1 interval.
RESULTS: The present study included 71 patients in the intervention group and 49 in the control group, with no baseline group differences in outcomes. Compared with controls, the intervention group showed significantly larger improvements in depressive symptoms (p = .042, η2ₚ = 0.035), mental health-related quality of life (p = .014, η2ₚ = 0.064), social functioning (p = .005, η2ₚ = 0.084), and overall patient competence (p = .018, η2ₚ = 0.048). No group-by-time interaction effects were found for post-COVID symptom severity, fatigue, anxiety, or physical health-related quality of life. Within the intervention group, significant but small improvements were found for fatigue (p = .029, d = 0.275) and anxiety (p = .008, d = 0.324), alongside improvements in psychological outcomes.
DISCUSSION: A structured inpatient psychosomatic program can improve psychological well-being and coping competence in post-COVID patients with mental health comorbidities. While effects on physical symptoms were limited, strengthened coping resources may facilitate longer-term stabilization.
TRIAL REGISTRATION: German Clinical Trial Register (DRKS), retrospectively registered: 15.02.2024; DRKS-ID: DRKS00033562.
METHODS: In this prospective non-randomized controlled trial, patients with confirmed post-COVID syndrome were recruited from a specialized Post-COVID Center and allocated, based on treatment preference, either to a five-week multimodal inpatient psychosomatic program (intervention group) or to treatment-as-usual without inpatient psychosomatic care (control group). Outcomes were assessed at baseline (T0) and after five weeks (T1). Measures included post-COVID symptom severity (PCS score), fatigue (FSS), depressive symptoms (PHQ-9), anxiety (GAD-7), health-related quality of life (SF-36), and illness-related coping competence (PCQ-2). Group differences over time were analyzed using repeated-measures analysis of covariance, controlling for the T0-T1 interval.
RESULTS: The present study included 71 patients in the intervention group and 49 in the control group, with no baseline group differences in outcomes. Compared with controls, the intervention group showed significantly larger improvements in depressive symptoms (p = .042, η2ₚ = 0.035), mental health-related quality of life (p = .014, η2ₚ = 0.064), social functioning (p = .005, η2ₚ = 0.084), and overall patient competence (p = .018, η2ₚ = 0.048). No group-by-time interaction effects were found for post-COVID symptom severity, fatigue, anxiety, or physical health-related quality of life. Within the intervention group, significant but small improvements were found for fatigue (p = .029, d = 0.275) and anxiety (p = .008, d = 0.324), alongside improvements in psychological outcomes.
DISCUSSION: A structured inpatient psychosomatic program can improve psychological well-being and coping competence in post-COVID patients with mental health comorbidities. While effects on physical symptoms were limited, strengthened coping resources may facilitate longer-term stabilization.
TRIAL REGISTRATION: German Clinical Trial Register (DRKS), retrospectively registered: 15.02.2024; DRKS-ID: DRKS00033562.